FYI - For Your Innovation
Crispr Approval, Gemini, and Grok | The Brainstorm EP 27
Dec 13, 2023
Ali Urman, ARK Analyst, joins the discussion on the breakthrough in Crispr gene editing. The podcast also covers Google's Gemini and Twitter's Grok, as well as the approval of America's first gene-editing therapy, Casgevy. They explore the differences between gene editing and gene therapy, debate the controversy surrounding Gemini's marketing, and discuss the value accrual in new technology.
22:27
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The FDA has approved America's first gene-editing therapy, Casgevy, for the treatment of sickle cell disease, offering a potential cure for this genetic condition.
- Google's Gemini, a large language model trained for multimodal capabilities, showcases the future potential of AI-powered digital assistants to better understand and interact with humans.
Deep dives
First ever gene editing approval for sickle cell disease
The FDA has approved the first gene editing therapy called Kishjavi, developed by CRISPR Therapeutics and Vertex Pharmaceuticals, for the treatment of sickle cell disease. The therapy targets the BCL-11a gene and aims to turn back on fetal hemoglobin production. This breakthrough therapy has the potential to provide a cure for sickle cell disease, which affects around 100,000 people in the US and 20 million people worldwide.
